ArticleOncology letters2018
Mechanism of the enhancing effects of miR-93 on resistance of breast cancer MCF-7 cells to adriamycin.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.Molecular oncology · 2019Trial
- Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.Functional & integrative genomics · 2024Review
- MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.Frontiers in pharmacology · 2024Review
- Radiation prevents tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑κB pathway in triple‑negative breast cancer.Oncology reports · 2023Article
- MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1.Cell death & disease · 2020Article
- Flaming the fight against cancer cells: the role of microRNA-93.Cancer cell international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the effects of miR-93 on resistance of breast cancer MCF-7 cells to adriamycin, and to explore the possible mechanism. Expression of miR-93 in breast cancer cell lines MCF-7 and MCF-7/ADM was detected by reverse transcription-quantitative PCR (RT-qPCR). miR-93 mimics and inhibitors were transfected into MCF-7/ADM and MCF-7 cells, and MTT assay was used to detect the resistance of cells to adriamycin after transfection. Western blot analysis was used to detect the expression of anti-apoptotic protein Bcl-2 and multidrug resistance gene MDR1 related P-gp protein in MCF-7/ADM and MCF-7 cells before and after the transfection of miR-93 mimics. Expression level of miR-93 in MCF-7/ADM cells was decreased, and was 40% of that in MCF-7 cells (0.39±0.04, p<0.05). Before transfection, IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.